High LDL Cholesterol

High LDL Cholesterol is one of the modifiable risk factors tracked by the IHME Global Burden of Disease Study. The attributable deaths shown here represent the estimated number of deaths that could be prevented if exposure to this risk factor were eliminated or reduced to optimal levels. Understanding risk factor contributions helps prioritize public health interventions and policy decisions.

Risk factor attribution uses comparative risk assessment methodology. A single death may be partially attributed to multiple risk factors, so attributable death counts should not be summed across risk factors. Data covers 204 countries from 1990 to the latest available year.

Elevated low-density lipoprotein (LDL) cholesterol is a major causal risk factor for atherosclerotic cardiovascular disease, contributing to approximately 4.4 million deaths per year from ischaemic heart disease and stroke. Globally, raised total cholesterol (over 5.0 mmol/L) affects approximately 39% of adults. Dietary saturated fat and trans-fat intake, obesity, physical inactivity, and genetic factors (including familial hypercholesterolaemia, which affects 1 in 250 people) are the primary determinants. Cholesterol levels have declined in high-income Western countries over recent decades — reflecting dietary changes and statin use — but are rising in East and Southeast Asia as diets westernise. The causal relationship between LDL cholesterol and atherosclerosis is one of the best-established in cardiovascular medicine, supported by Mendelian randomisation studies, prospective cohorts, and randomised clinical trials. Every 1 mmol/L reduction in LDL cholesterol lowers cardiovascular event risk by approximately 22%.

High LDL Cholesterol contributes to mortality from ischaemic heart disease, ischaemic stroke, peripheral arterial disease. The magnitude of impact varies by country depending on exposure levels, population demographics, and the availability of preventive and treatment services.

Statins are the cornerstone of pharmacological cholesterol management, with proven cardiovascular mortality reduction in both primary and secondary prevention. Trans-fat elimination (WHO REPLACE initiative) is a highly cost-effective population-level intervention. Dietary guidance to replace saturated fats with unsaturated fats, increase fibre intake, and reduce processed food consumption lowers LDL. PCSK9 inhibitors and bempedoic acid provide additional LDL lowering for high-risk patients. Cascade screening for familial hypercholesterolaemia enables early treatment of those at highest risk.